#USA #Cambridge #PhaseV #AI Orchestrator #BonV

PhaseV Launches BonV: Transforming Clinical Development

PhaseV has recently introduced BonV, an agentic AI orchestrator engineered to streamline the clinical development process by converting clinical inquiries into defensible decisions. This innovative tool leverages AI and causal machine learning, enhancing the ability of biopharma companies to make faster and more informed decisions.

BonV serves as a robust bridge between clinical teams, consolidating varying data and tools into a single, connected workspace. This integration allows trial teams to ask specific clinical questions in more straightforward language, enabling BonV to process inputs and yield evidence-based recommendations.

Centralized Workspace for Decision-Making

In collaboration with its Forward Deployed Engineers, BonV caters to the myriad intricacies involved in trial decisions. As Raviv Pryluk, PhD, CEO of PhaseV, articulates, the decision-making process often relies on data scattered across different teams and platforms. BonV’s capacity to collate this information into one user-friendly interface is a game-changer for clinical trials.

The AI tool is designed to address a spectrum of development inquiries, from critical go/no-go assessments to nuanced trial designs. For instance, one team wrestling with a Phase 2 obesity asset used BonV to devise a strategic development plan. The AI not only clarified the primary objective but also engaged with team members to gather necessary context, subsequently proposing a detailed roadmap addressing clinical, statistical, and operational concerns.

BonV employs phase-oriented models, wherein it evaluates and simulates various development strategies based on multiple criteria, such as time efficiency, patient impact, and operational complexity. The final output includes a recommendation supported by detailed evidence, culminating in a comprehensive decision memo that outlines the rationale behind pivotal choices.

Designed for Pharma Enterprises

Another notable feature of BonV is its compatibility with existing pharmacy tools and technologies, allowing it to extend the functionalities of current investments rather than replacing them. With seamless integration capabilities via API, BonV transforms the work environment into a cohesive unit where multiple users can track project roles, responsibilities, and expenditures, ensuring transparency and governance in budget management.

PhaseV has already seen impressive outcomes through pilot projects facilitated by BonV, including a remarkable $32 million reduction in trial costs, alongside an expedited timeline for trial completion by up to eight months. Furthermore, BonV has played a significant role in supporting investment due diligence processes, effectively streamlining decision-making for high-stakes transactions.

Availability and Future Prospects

Currently, BonV is being utilized by selected pharmaceutical enterprises, and PhaseV has initiated a phased rollout geared toward wider distribution. This strategic expansion includes integrating BonV with existing systems, assisted by the knowledgeable PhaseV team, ensuring a smooth operational transition for users. Existing PhaseV modules remain available, allowing clients the flexibility to subscribe to standalone services as needed.

PhaseV has carved a niche in the clinical development space since its inception in 2023, working alongside over 50 global sponsors, including 10 major pharmaceutical firms. With the assistance of multi-disciplinary experts, PhaseV has successfully reduced development costs and increased trial success rates.

As the landscape of clinical trials evolves, tools like BonV represent a significant advancement in facilitating more coherent, defendable decision-making processes aimed at improving patient outcomes and operational efficiency. To find out more or to schedule a demo of BonV, visit the PhaseV website at www.phasevtrials.com/contact.